ICER releases draft evidence report on cost effectiveness of myasthenia gravis treatments
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news
Durvalumab-induced Myocarditis, Myositis, and Myasthenia Gravis Durvalumab-induced Myocarditis, Myositis, and Myasthenia Gravis
This case reviews the diagnostic workup and management of a patient with severe immune-related adverse effects due to the immune checkpoint inhibitor durvalumab.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Potential First-in-Class, Targeted Therapy for Myasthenia Gravis Potential First-in-Class, Targeted Therapy for Myasthenia Gravis
Efgartigimod is linked to clinically meaningful improvements in strength and quality of life in patients with generalized myasthenia gravis, the phase 3 ADAPT trial shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 18, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
What Are Some Indications for Using Dexamethasone?
Discussion
Corticosteroids are a group of drugs which can be naturally or synthetically produced. Naturally occurring substances are produced in the adrenal gland, and are protein-bound (primarily corticosteroid-binding globulin and albumin). In the target tissues, they may need to be converted to an active substance. They are then reduced, oxidized, hydroxylated or conjugated as measures to inactivate them. Synthetic steroids have less protein binding and depending on their structure are more or less resistant to inactivation. Prednisone is the glucocorticoid most often used for treatment, especially as it has a short hal...
Source: PediatricEducation.org - June 7, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Pembrolizumab-induced Myasthenia Gravis-like Disorder Pembrolizumab-induced Myasthenia Gravis-like Disorder
This case suggests that concomitant use of low-dose steroids and pembrolizumab might prevent neurocomplications of checkpoint inhibitor therapy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 20, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
New Steroid Dosing Regimen for Myasthenia Gravis New Steroid Dosing Regimen for Myasthenia Gravis
The use of a new rapid tapering regimen resulted in a lower cumulative dose of prednisone with similar clinical outcomes in a new randomized study.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 16, 2021 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news
What Causes Lethargy?
Discussion
Lethargy is a common word used to describe a person who is drowsy, sluggish, listless and apathetic. Concentration may be difficult and they may have problems doing simple tasks. Many people actual mean fatigue or lassitude or being more tired when they use the word. In medical terms, lethargy is usually used to describe patients who have some type of excessive tiredness and usually have mental status changes with decreased alertness or arousal. Patients and health care providers both usually qualify the term and give more description to better communicate what is implied when using the term. This is true of man...
Source: PediatricEducation.org - January 25, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Ocular Side Effects Possible With Checkpoint Inhibitors Ocular Side Effects Possible With Checkpoint Inhibitors
People who use immune-checkpoint inhibitors have an increased risk of noninfectious uveitis and myasthenia gravis, according to a database study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutaneous for...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
COVID-19 Linked to Development of Myasthenia Gravis COVID-19 Linked to Development of Myasthenia Gravis
Three patients with no prior neurologic or autoimmune disorders developed myasthenia gravis within a week after onset of fever from SARS-CoV-2 infection.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 19, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen ’s Leadership in Novel Treatments for Autoimmune Diseases
NEW BRUNSWICK, N.J., August 19, 2020 – Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease. The transaction will include full global rights to nipocalimab (...
Source: Johnson and Johnson - August 19, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Patients with recently discovered antibodies have more severe myasthenia gravis
(Medical College of Georgia at Augusta University) A study of 181 patients at 16 sites across the country who test negative for two antibodies long known to cause muscle-weakening myasthenia gravis, found that about 15% test positive for one of two newly discovered antibodies that also attack the point of communication between nerves and muscle. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 19, 2020 Category: International Medicine & Public Health Source Type: news
Coronavirus: Severe cases could trigger autoimmune disease
A case report from Garibaldi Hospital in Catania, Italy, tracked three coronavirus patients who were subsequently diagnosed with myasthenia gravis one week after fever onset. (Source: the Mail online | Health)
Source: the Mail online | Health - August 17, 2020 Category: Consumer Health News Source Type: news
What Causes Myasthenia Gravis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 22, 2020 Category: General Medicine Source Type: news
Rituximab Promising in New-Onset Myasthenia Gravis Rituximab Promising in New-Onset Myasthenia Gravis
New research suggests rituximab is safer and more effective than immunosuppressants for myasthenia gravis, especially in new-onset disease.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 11, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
